Page last updated: 2024-08-24

topotecan and canertinib

topotecan has been researched along with canertinib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Bible, KC; Boerner, SA; Erlichman, C; Hallgren, CG; James, CD; Kaufmann, SH; Maliepaard, M; Ross, DD; Scheffer, GL; Spieker, R; Wang, XY	1

Other Studies

2 other study(ies) available for topotecan and canertinib

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer research, 2001, Jan-15, Volume: 61, Issue:2 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Cycle; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Neoplastic Stem Cells; Phosphorylation; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay	2001

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

Cancer research, 2001, Jan-15, Volume: 61, Issue:2

Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Cycle; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Neoplastic Stem Cells; Phosphorylation; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay

2001